-

Bayer Donates $500K to Support Maui Community After Devastating Fires

  • Cash and Essential Healthcare Products Donation Aims to Aid Relief Efforts

WHIPPANY, N.J.--(BUSINESS WIRE)--In the aftermath of the devastating fires that have affected the Maui community, Bayer stands in solidarity with those impacted and offers heartfelt condolences for the losses endured. With roots spanning more than 50 years in Maui County, Bayer is firmly committed to providing immediate relief and sustained support for recovery and rebuilding.

Guided by its vision, 'Health for All, Hunger for None,' Bayer will contribute $500,000 to relief efforts on the island – a cash donation of $250,000 alongside a donation of essential healthcare products valued at $250,000.

This donation underscores Bayer’s dedication to addressing crucial needs of the community and the company’s Crop Science employees at our farms on Maui during this unimaginable time. It focuses on the key areas of supporting relief efforts, increasing access to food for those displaced and continuing to assess the needs of the community on an ongoing basis and contribute to local organizations as additional needs emerge.

Of the cash donation, $150,000 will be directed to the Hawaii Community Foundation's Maui Strong program, which plays a vital role in coordinating resources for recovery efforts. An additional $50,000 will be contributed to the Maui Food Bank, supporting their mission to provide relief and distribute food through community partners to assist those in need. Recognizing the evolving nature of the situation, Bayer will also provide $50,000 in future contributions to local organizations to help support the ongoing efforts as needs emerge.

To supplement donations made to local organizations, Bayer will donate vital healthcare supplies valued at $250,000 to Direct Relief, an organization working closely with 19 Hawaii healthcare partners to deliver immediate medical aid to those in need on the ground. The donation includes 4,000 essential items specifically requested by Direct Relief such as Bayer Aspirin, Aleve, Claritin, and an antibiotic, addressing critical healthcare requirements.

In addition to these contributions, Bayer's employees on Maui, Molokai, and Oahu have demonstrated remarkable compassion by donating more than 3,000 pounds of essential supplies, including food, water, toiletries, towels, baby items, sleeping bags, household necessities, and clothing. Many Bayer employees have also dedicated their time to contributing to the relief efforts by volunteering to serving meals and sorting donations, showcasing a genuine commitment to assisting their fellow community members.

Furthermore, colleagues across Bayer have united to show their support for Maui. Through the Bayer Fund matching program, employees have generously made monetary donations, with Bayer Fund matching these contributions. This collective effort underscores Bayer's commitment to standing alongside the Maui community during these trying times.

"We are grateful to be a part of the Maui community and are fully committed to providing support during this unprecedented time," stated Alan Takemoto, Government Affairs Lead, Bayer Hawaii. "Our pledge is to help offer not only immediate relief but also to contribute to the sustained recovery and revitalization of Maui."

As the journey toward recovery continues, Bayer remains dedicated to standing by the Maui community for years to come.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

About Bayer Fund

Bayer Fund, a philanthropic arm of Bayer in the U.S., is a nonprofit organization dedicated to strengthening the communities where Bayer customers and employees live and work by providing funding for food and nutrition, education, and health and wellness projects. For more Information visit https://www.fund.bayer.us.

Contacts

Brian Leake
Director, External Communications
Brian.Leake@Bayer.com
(314) 370.3285

Monica Ivey
Corporate Relations Lead
Bayer Hawaii
Monica.Ivey@Bayer.com
(808) 221.1166

Bayer


Release Versions

Contacts

Brian Leake
Director, External Communications
Brian.Leake@Bayer.com
(314) 370.3285

Monica Ivey
Corporate Relations Lead
Bayer Hawaii
Monica.Ivey@Bayer.com
(808) 221.1166

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom